Report: Indian Drug Makers Too Risk-Averse
This article was originally published in PharmAsia News
Executive Summary
PricewaterhouseCoopers, the U.S. accounting/consulting firm, says in a new report that Indian drug makers are not taking the risks they should for creating new treatments. The report cited a basic conflict between drug makers and governments over the price of drugs. The report noted pharmaceutical companies often are flying blind when they attempt to develop a new drug. The report urged governments to adopt policies that spur innovative research, and back that work with good intellectual-property laws. (Click here for more
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.